Straits Times Index
3,309.21 -12.87 (-0.39%) S&P 500
5,336.94 -23.85 (-0.44%) Dow
38,544.13 -323.91 (-0.83%) Nasdaq
17,157.12 -35.40 (-0.21%) Bitcoin USD
66,705.88 -2,680.93 (-3.86%) CMC Crypto 200
1,388.37 -53.27 (-3.69%)
Lexeo Therapeutics, Inc. (LXEO)
- Zacks
What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock
Lexeo Therapeutics, Inc. (LXEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Zacks
Wall Street Analysts Think Lexeo Therapeutics, Inc. (LXEO) Could Surge 57.82%: Read This Before Placing a Bet
The mean of analysts' price targets for Lexeo Therapeutics, Inc. (LXEO) points to a 57.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- GlobeNewswire
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
Closed an oversubscribed $95 million equity financing in March with Q1 2024 cash balance of $195.1 million at quarter-end, expected to provide runway into 2027 Completed in-license agreement with Cornell University for intellectual property rights, including current and future clinical data from an ongoing investigator-initiated trial of AAVrh.10hFXN (LX2006) to support regulatory discussions Interim readout of combined data set of LX2006 at multiple doses anticipated in mid-2024; Lexeo expects
